Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARWR Arrowhead Research Corporation

交易中 04-30 10:15:42 EDT

70.77

+0.24

+0.33%

最高72.16	最低69.15	成交量16.63万
今开71.25	昨收70.53	日振幅4.26%
总市值99.08亿	流通市值84.92亿	总股本1.40亿
成交额1,172万	换手率0.14%	流通股本1.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARWR","market":"US","secType":"STK","nameCN":"Arrowhead Research Corporation","latestPrice":70.765,"timestamp":1777558540132,"preClose":70.53,"halted":0,"volume":166298,"delay":0,"changeRate":0.003331915496951644,"floatShares":120000000,"shares":140010690,"eps":1.475114,"marketStatus":"交易中","change":0.235,"latestTime":"04-30 10:15:42 EDT","open":71.25,"high":72.155,"low":69.15,"amount":11721755.6621,"amplitude":0.042606,"askPrice":70.86,"askSize":34,"bidPrice":70.67,"bidSize":181,"shortable":3,"etf":0,"ttmEps":1.475114,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777579200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":740203200000,"exchange":"NASDAQ","adjPreClose":70.53,"preHourTrading":{"tag":"盘前","latestPrice":71.36,"preClose":70.53,"latestTime":"09:29 EDT","volume":1610,"amount":114454.8839,"timestamp":1777555799999,"change":0.83,"changeRate":0.011768,"amplitude":0.021126},"postHourTrading":{"tag":"盘后","latestPrice":70,"preClose":70.53,"latestTime":"16:50 EDT","volume":11189,"amount":788996.52,"timestamp":1777495804925,"change":-0.53,"changeRate":-0.007515,"amplitude":0.007515},"volumeRatio":0.849699,"impliedVol":0.7332,"impliedVolPercentile":0.8805},"requestUrl":"/m/hq/s/ARWR","defaultTab":"news","newsList":[{"id":"1134103027","title":"财报前瞻｜Arrowhead Research Corporation本季度营收预计增153.09%，机构多数看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1134103027","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134103027?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:22","pubTimestamp":1777533756,"startTime":"0","endTime":"0","summary":"Arrowhead Research Corporation将于2026年05月07日（盘后）披露财报，市场关注营收波动、利润弹性与合作里程碑兑现节奏。市场一致预期显示，本季度公司营收预计为7,569.00万美元，同比增长153.09%；调整后每股收益预计为-1.19美元，同比下降499.63%；息税前利润预计为-1.77亿美元，同比下降356.25%。发展前景中，Sarepta合作被视为最具驱动力的现有业务，当前其6.97亿美元的体量与高占比，叠加市场对本季度营收同比增长153.09%的预期，共同构成短期业绩的主要支撑与不确定来源。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Arrowhead Research Corporation本季度营收预计增153.09%，机构多数看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109095939","title":"Arrowhead制药公司：欧盟委员会关于Redemplo上市授权的决定预计将于2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1109095939","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109095939?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:43","pubTimestamp":1777027425,"startTime":"0","endTime":"0","summary":"Arrowhead制药公司近日透露，其备受关注的药物Redemplo的上市授权申请，已进入欧盟监管审批的关键阶段。根据最新进展，欧盟委员会对该药物作出的最终决定，预计将在2026年第二季度正式揭晓。\n这一重要时间点的明确，为市场评估该创新疗法的商业前景提供了清晰的路线图。监管机构的决定将对公司的未来发展产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128845645","title":"Arrowhead Pharmaceuticals 在欧洲获得针对家族性乳糜微粒血症综合征药物Plozasiran的积极CHMP意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1128845645","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128845645?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:41","pubTimestamp":1777027316,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其用于治疗家族性乳糜微粒血症综合征（FCS）的药物Plozasiran（研发代号：Redemplo）已获得欧洲药品管理局人用医药产品委员会（CHMP）的积极意见。这一积极意见是Plozasiran在欧洲监管审批进程中的关键一步，为后续获得欧盟委员会的上市批准奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143194222","title":"财报前瞻｜Arrowhead Research Corporation本季度营收预计增2.71%，机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1143194222","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143194222?lang=zh_cn&edition=full","pubTime":"2026-01-29 10:49","pubTimestamp":1769654950,"startTime":"0","endTime":"0","summary":"Arrowhead Research Corporation将于2026年02月05日发布最新季度财报，市场目光聚焦收入与盈利质量的变化及合作里程碑进展。市场一致预期本季度Arrowhead Research Corporation总收入为2.70亿美元，同比增长2.71%；调整后每股收益为0.25美元，同比增长157.81%；息税前利润为1.05亿美元，同比增长221.03%；由于目前未获得包含毛利率、净利润或净利率在内的本季度具体预测信息，相关指标不展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Arrowhead Research Corporation本季度营收预计增2.71%，机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138084094","title":"Arrowhead启动Aro-Dimer-Pa一期/二期a研究——首款双功能RNAi疗法瞄准混合型高脂血症","url":"https://stock-news.laohu8.com/highlight/detail?id=1138084094","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138084094?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:33","pubTimestamp":1769517180,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布启动其创新药物Aro-Dimer-Pa的一期/二期a阶段临床研究。该疗法作为全球首个双功能RNAi治疗药物，专门针对混合型高脂血症的临床需求而设计。\n此次研究标志着RNAi疗法领域的重要突破。Aro-Dimer-Pa通过独特的双功能机制，有望为现有治疗方案提供新的选择。混合型高脂血症作为常见代谢性疾病，其治疗手段的革新将可能惠及广大患者群体。\n临床研究的推进将重点评估该药物的安全性和初步疗效。随着试验的展开，医学界期待这一创新疗法能为血脂管理领域带来新的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ARWR","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129668005","title":"创新药板块的强心剂! Piper Sandler押注“基因沉默”领军者Arrowhead预言股价将狂飙55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129668005","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129668005?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:23","pubTimestamp":1768206185,"startTime":"0","endTime":"0","summary":"华尔街知名投资机构Piper Sandler近日发布研报称，维持对于Arrowhead Pharmaceuticals, Inc.的“增持”股票评级，同时还将该股的目标价格从70美元上调至100美元。Piper Sandler予以Arrowhead Pharmaceuticals的100美元这一12个月内无比强劲的看涨目标价位，堪称对于当前处于回调阶段的全球创新药领域的一针重磅强心剂。这也是Arrowhead的第一款获得FDA批准上市的药物，标志着其从临床阶段向商业化阶段的转变。该公司推出了用于FCS的Redemplo，来自Piper Sandler的分析师Edward Tenthoff指出。","market":"us","thumbnail":"https://static.tigerbbs.com/11076e6c3301a4665b618769514d271f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/11076e6c3301a4665b618769514d271f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1391483.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602560433","title":"创新药板块的强心剂! Piper Sandler押注“基因沉默”领军者Arrowhead(ARWR.US) 预言股价将狂飙55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602560433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602560433?lang=zh_cn&edition=full","pubTime":"2026-01-12 12:01","pubTimestamp":1768190468,"startTime":"0","endTime":"0","summary":"Piper Sandler予以Arrowhead Pharmaceuticals的100美元这一12个月内无比强劲的看涨目标价位，堪称对于当前处于回调阶段的全球创新药领域的一针重磅强心剂。今年以来Arrowhead Pharmaceuticals股价表现不佳，年内迄今跌近3%，大幅跑输标普500指数。这也是Arrowhead的第一款获得FDA批准上市的药物，标志着其从临床阶段向商业化阶段的转变。该公司推出了用于FCS的Redemplo，来自Piper Sandler的分析师Edward Tenthoff指出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","ARWR","BK4585","06978","BK4139","BK1161","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110969912","title":"Arrowhead制药盘前股价下跌3.4% 公司宣布股票发售与可转债发行计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1110969912","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110969912?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:19","pubTimestamp":1767791975,"startTime":"0","endTime":"0","summary":"Arrowhead制药（Arrowhead Pharmaceuticals）在宣布启动股票公开发售及可转换债券发行计划后，其股价在盘前交易时段应声下跌3.4%。此次融资举措旨在为公司研发管线及一般企业用途筹集资金，但市场对此反应消极，显示出投资者可能担忧股权稀释风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ARWR","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193438637","title":"Arrowhead制药子公司Visirna获NMPA批准，赛诺菲将支付1000万美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1193438637","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193438637?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:31","pubTimestamp":1767789075,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其子公司Visirna Therapeutics因获得中国国家药品监督管理局（NMPA）的相关批准，已触发由赛诺菲（Sanofi）支付的1000万美元里程碑款项。该笔资金将依据双方此前达成的协议条款进行支付。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197898682","title":"Arrowhead基因沉默药物在肥胖症早期临床试验中实现减脂效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1197898682","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197898682?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:43","pubTimestamp":1767706988,"startTime":"0","endTime":"0","summary":"1月6日，Arrowhead美股盘前涨超13%！公司的基因沉默药物在肥胖症早期临床试验中实现减脂效果。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c573bab846c0be6427fdc6152b80ce33","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Arrowhead基因沉默药物在肥胖症早期临床试验中实现减脂效果","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159721531","title":"Arrowhead制药公布RNAi减肥候选药物中期临床数据：糖尿病患者体重显著下降且体脂指标改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1159721531","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159721531?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:30","pubTimestamp":1767702618,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals最新发布的中期临床试验数据显示，其基于RNA干扰技术开发的肥胖症治疗候选药物在糖尿病合并肥胖患者群体中展现出显著疗效。研究结果表明，接受治疗的患者不仅实现体重下降，多项身体成分指标也获得明显改善。\n该数据进一步验证了RNAi疗法在代谢疾病领域的应用潜力。通过靶向特定基因表达，候选药物展现出精准调节体脂代谢的能力，为肥胖症治疗提供了新的技术路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c573bab846c0be6427fdc6152b80ce33","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174388970","title":"Arrowhead Pharmaceuticals宣布加拿大卫生部批准Redemplo™（Plozasiran）用于降低家族性乳糜微粒血症综合征成人患者甘油三酯水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1174388970","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174388970?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:33","pubTimestamp":1767616393,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其创新药物Redemplo™（Plozasiran）已获得加拿大卫生部批准，用于治疗成人家族性乳糜微粒血症综合征（FCS），显著降低患者体内的甘油三酯水平。这一重要监管里程碑为加拿大FCS患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","ARWR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111227253","title":"Arrowhead Pharmaceuticals启动Aro-Mapt治疗阿尔茨海默病及其他tau病的1/2a期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1111227253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111227253?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:31","pubTimestamp":1765197073,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals启动Aro-Mapt治疗阿尔茨海默病及其他tau病的1/2a期研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108529390","title":"Arrowhead Pharmaceuticals：计划在2026年底之前向FDA提交补充新药申请(SNDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=1108529390","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108529390?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:31","pubTimestamp":1764678684,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals：计划在2026年底之前向FDA提交补充新药申请(SNDA)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151824926","title":"异动解读 | 分析师看好新药Redemplo及肥胖症资产数据，Arrowhead Research盘中大涨26.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151824926","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151824926?lang=zh_cn&edition=full","pubTime":"2025-11-27 04:30","pubTimestamp":1764189022,"startTime":"0","endTime":"0","summary":"Arrowhead Research Corporation（ARWR）今日盘中大涨26.10%，成为纳斯达克生物技术指数中的领涨股之一。消息面上，TD Cowen分析师在报告中指出，ARWR虽然报告了2025财年的亏损，但公司势头强劲，其新药Redemplo（用于治疗家族性乳糜微粒血症综合征）已成功上市。此外，分析师还提到，公司关于肥胖症资产的初步数据将于明年1月初公布，进一步提振了市场信心。生物技术板块近期表现强劲，纳斯达克生物技术指数本季度已上涨约19%，ARWR的突出表现也反映了市场对其创新管线的乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129317410","title":"Arrowhead Pharmaceuticals宣布FDA批准Redemplo®（Plozasiran）用于降低家族性乳糜微粒血症（FCS）成人的甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1129317410","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129317410?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:52","pubTimestamp":1763484733,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布FDA批准Redemplo®（Plozasiran）用于降低家族性乳糜微粒血症（FCS）成人的甘油三酯。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121748631","title":"FDA批准Redemplo用于降低家族性乳糜微粒血症患者的甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1121748631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121748631?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:17","pubTimestamp":1763482634,"startTime":"0","endTime":"0","summary":"FDA批准Redemplo用于降低家族性乳糜微粒血症患者的甘油三酯。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516727646","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 急速跳水5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516727646","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516727646?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099028,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.14%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Capricor Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1088.65%、1075.19%、426.90%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Adma Biologics Inc，振幅分别为23.30%、22.25%、12.57%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223709abe7f1a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223709abe7f1a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARWR","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513472704","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513472704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513472704?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:02","pubTimestamp":1740409374,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时02分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.08%。截至发稿，该股报18.89美元/股，成交量10.6991万股，换手率0.08%，振幅4.92%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Avalo Therapeutics, Inc.涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为156.52%、69.90%、25.47%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230254a2521c2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230254a2521c2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARWR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166835000","title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1166835000","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166835000?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:58","pubTimestamp":1740045485,"startTime":"0","endTime":"0","summary":"罗氏计划今年启动中期试验，将其与自研GLP-1减肥候选药CT-388联用。BiohavenBiohaven在一项早期肥胖试验中评估其靶向肌肉生长抑制素的药物taldefgrobep alfa。该药虽未改善脊髓性肌萎缩症患者的运动功能，但减少了总体脂肪量，并在去脂体重和骨密度方面优于安慰剂。公司将在男性肥胖患者的早期研究中评估安全性，数据预计2025年一季度公布。","market":"us","thumbnail":"https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","SRRK","ARWR","ELAB","REGN","KROS","AZN","VERU","LLY"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.arrowheadpharma.com","stockEarnings":[{"period":"1week","weight":-0.0459},{"period":"1month","weight":0.2234},{"period":"3month","weight":0.0204},{"period":"6month","weight":0.6638},{"period":"1year","weight":4.2361},{"period":"ytd","weight":0.0624}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立，后在特拉华州重新注册成立。该公司开发药物，通过沉默疾病的基因来治疗疑难杂症。使用广泛的RNA化学组合和高效的递送模式，该公司的疗法触发RNA干扰机制，以诱导目标基因的快速、深度和持久敲低。目前有18个Arrowhead发现的候选药物处于早期（1期）至晚期（3期）的临床试验阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009831},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.008632},{"month":3,"riseRate":0.5,"avgChangeRate":0.050374},{"month":4,"riseRate":0.5,"avgChangeRate":0.030374},{"month":5,"riseRate":0.380952,"avgChangeRate":0.008317},{"month":6,"riseRate":0.571429,"avgChangeRate":0.023453},{"month":7,"riseRate":0.571429,"avgChangeRate":0.054423},{"month":8,"riseRate":0.428571,"avgChangeRate":0.013202},{"month":9,"riseRate":0.52381,"avgChangeRate":0.064131},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.028468},{"month":11,"riseRate":0.545455,"avgChangeRate":0.060925},{"month":12,"riseRate":0.454545,"avgChangeRate":0.054899}],"exchange":"NASDAQ","name":"Arrowhead Research Corporation","nameEN":"Arrowhead Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arrowhead Research Corporation,ARWR,Arrowhead Research Corporation股票,Arrowhead Research Corporation股票老虎,Arrowhead Research Corporation股票老虎国际,Arrowhead Research Corporation行情,Arrowhead Research Corporation股票行情,Arrowhead Research Corporation股价,Arrowhead Research Corporation股市,Arrowhead Research Corporation股票价格,Arrowhead Research Corporation股票交易,Arrowhead Research Corporation股票购买,Arrowhead Research Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}